The 9 most recent market catalysts affecting $SION, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029
Sionna Therapeutics is making a significant strategic shift by advancing its SION-451/SION-2222 dual combination into a Phase 2a trial for cystic fibrosis, based on promising post …
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 75
Wedbush Downgrades Sionna Therapeutics to Neutral, Lowers Price Target to $5
Wedbush analyst Laura Chico downgraded Sionna Therapeutics (SION) from Outperform to Neutral and slashed the price target from $53 to $5. This dramatic revision indicates a signifi…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
Sionna Therapeutics' primary drug candidate, SION-719, failed to meet its key primary activity target in a Phase 2a trial for cystic fibrosis. This failure led the company to immed…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
12 Health Care Stocks Moving In Monday's Pre-Market Session
The filing details substantial pre-market price swings for 12 healthcare stocks, with several experiencing gains or losses exceeding 20%, and some even over 70% or 90%. These movem…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Sionna Therapeutics shares are trading lower after the company reported topline data from the PreciSION CF Phase 2a proof-of-concept trial of SION-719 did not achieve key activity endpoint.
The failure of SION-719 to achieve its key activity endpoint in a Phase 2a trial is a devastating blow for Sionna Therapeutics. For a clinical-stage biotech company, the success of…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating on Sionna Therapeutics and raised the price target from $50 to $60. This upgrade signals a more optimistic outlook from a …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Sionna Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate
Sionna Therapeutics (SION) announced a Q2 EPS loss of $(0.66), which missed the consensus estimate of $(0.65) by 1.54%. More significantly, this loss represents a 60.98% decrease (…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.